Adagene Inc.
ADAG Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.49
KIRA · Stoqly’s AI analyst, in plain words
- Adagene Inc. had $7.7M of revenue in fiscal 2025, up 7,333.0% on the year before. Over five years, revenue changed +61.4% a year on average.
- Its operating margin was −279.5%, up 34,557.2 pts: of every 100 in sales, about −279 is left after running the business.
- Adagene Inc. lost $17.6M in fiscal 2025.
- Free cash flow was −$15.7M in fiscal 2025, −204.3% of revenue.
- Adagene Inc. has $67.7M more cash than debt.
Market cap
$147M
P/E
—
Revenue
$7.7M
Net income
−$17.6M
Free cash flow
−$15.7M
Operating margin
−279.5%
Adagene Inc. in 30 seconds · fiscal 2025
Are sales growing?
+7,333.0%
Yes. Sales grew 7,333.0% last year.
Does it make a profit?
−229.6%
No. It lost money last year.
Does profit turn into cash?
−204.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Adagene Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 1, 2026
- Legal name
- Adagene Inc.
- CIK
- 0001818838
Adagene Inc. · ADAG
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $10.2M | $9.3M | $18.1M | $0.1M | $7.7M |
| Revenue growth | 1,351.7% | −8.7% | 94.9% | −99.4% | 7,333.0% |
| Operating margin | −711.2% | −903.1% | −131.0% | −34,836.7% | −279.5% |
| Net income | −$73.2M | −$80.0M | −$18.9M | −$33.4M | −$17.6M |
| Net margin | −719.2% | −860.6% | −104.6% | −32,387.7% | −229.6% |
| Diluted EPS | −$1.46 | −$0.31 | −$0.35 | −$0.59 | −$0.30 |
| Cash | |||||
| Cash from operations | −$43.4M | −$48.6M | −$28.5M | −$29.7M | −$15.7M |
| Capital expenditure | $2.5M | $0.7M | $0.1M | $0.0M | $0.0M |
| Free cash flow | −$45.9M | −$49.3M | −$28.5M | −$29.7M | −$15.7M |
| FCF margin | −451.3% | −530.6% | −157.6% | −28,812.6% | −204.3% |
| Share buybacks | $2.4M | $4.0M | — | — | — |
| Share count change | 213.7% | 10.4% | −0.9% | 2.8% | 4.8% |
| Debt and strength | |||||
| Cash and short-term investments | $174M | $144M | $110M | $85.2M | $74.5M |
| Debt incl. finance leases | $8.9M | $30.6M | $26.1M | $31.1M | $6.8M |
| Shareholders' equity | $157M | $83.1M | $70.6M | $50.5M | $35.3M |
| Current ratio | 6.2x | 2.7x | 3.6x | 2.3x | 3.1x |
| Interest coverage | −198.9x | −121.0x | −21.4x | −42.2x | −46.3x |
| Returns and quality | |||||
| Return on equity | −217.9% | −66.7% | −24.7% | −55.2% | −41.0% |
| Return on tangible equity | −46.8% | −96.2% | −26.9% | −66.2% | −49.8% |
| Piotroski F-score | 5 | 2 | 4 | 1 | 5 |
| Altman Z'' | 4.8 | −3.9 | −2.9 | −9.1 | −9.8 |
Insiders bought, 12 months
$0.2M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Adagene Inc. · ADAG
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.49 a share, the company is worth $147M.
Source: SEC EDGAR XBRL filings (CIK 0001818838). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.